Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
Academic Article
Overview
MeSH Major
Anilides
Antineoplastic Agents
Liver Diseases
Neoplasms
Pyridines
abstract
Hepatic impairment does not appear to impact vismodegib PK, and therefore, dose adjustment is not necessary in this special population. The study was influenced by the high number of patients with hepatocellular carcinoma with advanced cirrhosis; rendering it difficult to draw any causal relationships between vismodegib exposure and the serious adverse events.
